Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares reached a new 52-week low during trading on Friday. The company traded as low as GBX 34 and last traded at GBX 34.25, with a volume of 49,095 shares. The stock had previously closed at GBX 36.
Faron Pharmaceuticals Oy Price Performance
The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15. The company has a market cap of £69.49 million, a price-to-earnings ratio of -2.97 and a beta of 1.12. The company has a fifty day simple moving average of GBX 37.53 and a two-hundred day simple moving average of GBX 41.15.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Recommended Stories
- Five stocks we like better than Faron Pharmaceuticals Oy
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
